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Role of psychological and emotional 
factors in cancer related fatigue 
(CRF) syndrome in advanced 
NSCLC patients undergoing 
palliative chemotherapy
Abstract
Background: Cancer-related fatigue syndrome (CRF) is observed in most cancer patients, especially in those 
with advanced disease. Pathomechanism of CRF is complex and not fully understood. The aim of the study 
was to determine the role of psychological and emotional factors in CRF in non small-cell lung cancer (NSCLC) 
patients at advanced stage of the disease undergoing chemotherapy. 
Material and methods: 76 patients with locally advanced or metastatic NSCLC, undergoing palliative 
chemotherapy participated in the study. Prior to, during and after the treatment, the patients were asked 
to complete psychological questionnaires, like HADS, CERQ and daily diary constructed for the purpose of 
this study. 
Results: Coping strategies like concentrating on other positive aspects and acceptance are factors, which 
positively, while catastrophising, anxiety and depression – negatively, characterise the level of perceived 
cancer related fatigue. 
Conclusions: Results show that some coping and emotional strategies as well as psychological features may 
constitute predictors for CRF. It may suggest that psychological features can influence the performance 
status of patients and reduce fatigue perceived by patients. Further research is needed to fully explained 
the phenomenon. 
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Introduction
According to the World Health Organization, lung 
cancer is the most common malignancy worldwide 
since every year about 1 200 000 new cases of the 
disease are reported. Lung cancer is also one of 
the most frequent causes of death [1]. Namely, the 
report from 2008 reveals that lung cancer is now 
the forth cause of death in high-income countries, 
the fifth in middle-income countries, and the eighth 
globally. In Poland five-year survival of lung cancer 
patients is as low as 14% [2].
Cancer related fatigue syndrome (CRF) has not 
received a single and comprehensive definition yet. 
One of them proposed by Cella et al [3], based on 
the most widely known features of fatigue, says that 
it is “a subjective state of an intensive and sustained 
exhaustion and reduced capacity for physical and 
mental work, which do not disappear after the rest”. 
Cancer related fatigue occurs in 70–100% of pa-
tients undergoing different types of anticancer therapy 
[4, 5]. Approximately 60–90% of patients suffer from 
CRF during chemotherapy, and 75–100% in the case 
of radiation treatment [6]. The incidence of CRF is not 
limited exclusively to patients with poor performance 
status (PS). Symptoms of this syndrome are also ob-
served in patients with good and very good PS (WHO 
0–1) as well [4, 5]. The frequency of CRF usually in-
creases during chemotherapy, however in patients with 
small cell lung cancer administration of such a treat-
ment results in reducing the incidence of CRF [7]. 
Consequences of CRF for cancer patients are very 
serious — they affect the physical life, but also - psy-
chological and social ones. This syndrome leads to 
a reduction in daily activities in more than 80% of 
cancer patients. That weakness, often called by the 
patients “fatigue”, lowers their ability to concentrate, 
thus additionally obstructing their daily function-
ing. Weakness experienced by cancer patients is not 
relieved by rest or sleep [8], however it is not the 
only symptom of CRF. The National Comprehensive 
Cancer Network Fatigue Practice Guidelines distin-
guished seven factors, which have been identified 
as the most common in the pathogenesis of cancer 
fatigue: pain, emotional distress, sleep disturbances, 
anaemia, nutrition deficiencies, reduced physiolog-
ical adaptability and diseases co-occurrence [9]. 
Cancer related fatigue has been treated as a set of 
various symptoms occurring for a long time. In the 
group of 51 lung cancer patients who successfully 
underwent chemotherapy, the intensity of the whole 
group of factors, such as fatigue, cancer, depres-
sion and pain was evaluated. Results indicate that 
fatigue was the most frequently emerging symptom, 
strongly correlated with depression. Both of these 
symptoms accounted for 29% of the variance of 
quality of life (p < 0.01) [10].
Pathomechanism of CRF development has not 
been explicitly explained as yet [11, 12]. Cancer 
related fatigue is often directly related to either the 
progression of cancer or anticancer treatment, such 
as chemo-and/or radiotherapy. One of the better 
recognized factors predisposing to the development 
of CRF is anaemia. Polish study (POLCAS) involving 
patients receiving chemotherapy or chemoradio-
therapy revealed that 31% of them suffered from 
anaemia prior to the treatment, while it occurred in 
54% of the patients after the treatment cessation. In 
the case of lung cancer patients, anaemia was rec-
ognised in one third of them prior to the treatment 
and in as much as 75% of the patients after the 
treatment administration [13]. However, not every 
patient with anaemia suffers from weakness [12, 14, 
15]. Of note, intensity of weakness in patients with 
anaemia also correlates with such symptoms as anxi-
ety, depression, pain or shortness of breath [16]. In 
a pilot study, where 24 cancer patients undergoing 
palliative radiotherapy were asked to complete a se-
ries of psychological questionnaires prior to and after 
the treatment, results showed correlation between 
temperament and strategies of coping with disease 
with the level of fatigue [17].
Cancer related fatigue syndrome is one of the 
dominant complaints reported by patients with 
cancer, including lung cancer. Unfortunately, only 
a few studies provided compelling evidence on the 
effective treatment of this syndrome. Among the 
promising treatment options of CRF are e.g. thera-
pies based on physical exercises, administration of re-
combinant human erythropoietin, psychotherapeutic 
and psychosocial interventions, and pharmacologi-
cal stimulation. Other solutions, such as therapy 
with growth hormone, androgen, L-carnitine, or 
anti- inflammatory agents must be treated as pilot 
concepts, which could be implemented exclusively 
in the context of controlled clinical trials [7].
Objective of the study
The aims of the study were to obtain answers to 
the following questions:
—  does NSCLC patient’s emotional state characterise 
the subjective perception of CRF level during pal-
liative chemotherapy?
— do the strategies for coping with the disease 
applied by the patients impact the subjective 
perception of CRF?
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— what are the differences in positive and negative 
psychological features of fatigue perceived by 
lung cancer patients? 
Material and methods
Participants
The study was conducted in two oncology clinics: 
Lung & Thoracic Tumours Department, The Maria 
Sklodowska-Curie Memorial Cancer Centre & In-
stitute, Warsaw, Poland, and  3rd Pulmonary Clinic, 
National Tuberculosis & Lung Diseases Research In-
stitute, Warsaw, Poland, in the period from July 
2007 to January 2010. Patients diagnosed with 
locally advanced or metastatic NSCLC, with perfor-
mance status (PS) according to ECOG/WHO from 0 
to 2, and qualified for palliative chemotherapy were 
included into the study. The study was a prospec-
tive, non-interventional and observational one. It 
was designed for 7 visits: six, during routine control 
visits when patients were given the standard pal-
liative treatment — multidrug chemotherapy and 
seventh — follow-up visit — 6–8 weeks after the 
therapy cessation. Only those patients who had re-
ceived at least 3 cycles of chemotherapy were invited 
for the follow-up visits. The following variables were 
chosen for this analysis: emotional and psychological 
traits and strategies. During the study, patients were 
filling in the set of psychological questionnaires, 
namely: Cognitive Emotion Regulation Questionnaire 
(CERQ), The Hospital Anxiety and Depression Scale 
(HADS) and specially prepared for this particular 
study patients’ daily diary for self-assessment of 
fatigue level. The patients were able to self-fill daily 
diaries and a set of psychological questionnaires. 
At the first visit 76 patients at the age ranged 
42–78 (M = 60.68 years, SD = 8.09) were enrolled, 
while 51 patients participated (M = 60,73 years; 
SD = 8.41) in follow-up visit. The group constituted 
from 38.16% women and 61.84% men. The most 
common causes of earlier termination of the treat-
ment were disease progression (N = 18; 23.7%) 
and adverse events occurrence resulted from the 
treatment (N = 17; 22.4%). Two patients died (2.6%) 
and two resigned from participation in the study 
prior to the follow-up visit (2.6%). The study group 
was characterized by various clinical stage of the 
disease (Table 1).
Approximately half of the patients (51%) who 
underwent the whole treatment (all six cycles of 
chemotherapy), completed the survey with good 
performance status (PS = 0), 41% respondents with 
PS = 1, and 5,9% of them with PS = 2. One patient 
during the follow-up visit was in PS = 4. 
The study was approved by the Ethical Review 
Board (R-I-002/238/2007) of Medical University of 
Białystok, Poland. Written consent was obtained 
from the patients.
Measures
In the study document analysis methods based on 
the questionnaire prepared for the sake of the study 
were employed, as well as questionnaire methods, 
i.e. standardised psychological questionnaires: 
— Cognitive Emotion Regulation Questionnaire 
(CERQ) constructed by Garnfelski, Kraaji and 
Spinhoven in 2001 [18], in Polish adaptation 
by Marszał-Wiśniewska and Fajkowska-Stanik 
(2007). It allows for measuring 9 cognitive emo-
tion regulation strategies: blaming yourself, 
blaming others, catastrophising, rumination, ac-
ceptance, concentration on other positive aspect, 
concentration on planning, positive reinterpreta-
tion and putting into perspective. In addition, 
these strategies can be divided into two groups: 
adaptive and non-adaptive [19]. The question-
naire was completed by the patients at each visit;
— The Hospital Anxiety and Depression Scale (HAD 
Scale) by Zigmond and Snaith (1983), in the Polish 
adaptation by Majkowicz, de Walden-Gałuszko 
and Chojnacka-Szawłowska (1994) [18]. The scale 
contains 14 questions with 4 response options. 
The scale was completed by the patients partici-
pating in the study at each visit;
Table 1. Group characteristic according to clinical stage of the disease: Staging of Non-small Cell Lung Cancer 
based on 6th edition of that classification used 
Total Women Men
IIIA 10 (13.2%) 5 (17.2%) 5 (10.6%)
IIIB 17 (22.4%) 5 (17.2%) 12 (25.5%)
IV 49 (64.5%) 19 (65.5%) 30 (63.8%)
Total 76 (100.0%) 29 (100.0%) 47 (100.0%)
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— Self-assessment Health Diary — a tool created 
specifically for this study to measure subjec-
tive (perceived by patients) level of fatigue and 
symptoms accompanying the disease during che-
motherapy and a follow-up visit. Patients were 
asked to observe themselves and assess the weak-
ness level (4 questions) daily and the state of 
weakness during the last week (8 questions). 
Answers to the questions related to the fatigue 
level were coded on a 5-point Likert’s scale (Cron-
bach alpha a = 0.854).
Statistical methods
Statistical analysis was performed with the use 
of the statistical package SPSS 14PL, 18PL and 
17EN. Results were considered significant when p-
value < 0,05. In addition, due to a relatively small 
studied group, the tendency of the results was ana-
lysed as well, with the p-value < 0,1.
For statistical analysis basic descriptive statis-
tics and multiple stepwise linear regression were 
employed. 
Results
Linear stepwise regression analyses were em-
ployed for searching for predictors of CRF occur-
rence among the psychological and emotional 
variables. A stepwise regression analysis showed 
that in the first two cycles of therapy a lack of 
ability to use “concentration on the other posi-
tive aspects” strategy is an important predictor of 
CRF occurrence. At a later stage of the treatment 
higher catastrophising and lack of acceptance of 
the disease as well increasing levels of anxiety 
and depression are predictors of CRF occurrence 
(Table 2 and 3).
It is noteworthy that at later cycles of chemo-
therapy predictors are stronger than those at the 
beginning of the treatment and that fact might 
be important for the interpretation of the results. 
Therefore, early stage of the therapy may possibly 
be more important for psychological intervention.
Discussion
The questions among psychological and emotion-
al patients’ profile, predictors of perceived CRF were 
investigated. The analysis showed that the positive 
(constructive) strategies for coping with the disease, 
are predictor of lower-level of CRF, while nega-
tive strategies, such as catastrophising, may cause 
a higher perception of the fatigue. This may suggest 
that through the influence on patients’ perception 
of illness and e.g. implementation of special training 
for patients, teaching them constructive strategies of 
coping with the situation of stress-induced cancer, 
it would be feasible to amend the perceived fatigue 
in NSCLC patients. 
It should be emphasized that the study had 
an exploratory nature. An undoubted advantage 
of this study was an attempt to include subjec-
tive nature (patients assessment and perception) 
of CRF syndrome, because as yet medical compo-
nents were unable to explain the whole characteris-
tic of this phenomenon. Consequently, it would be 
Table 2. Emotional and psychological predictors of cancer related fatigue in NSCLC patients undergoing 
chemotherapy
Cycle Model R R2 Adjusted R2 Model summary — Changes statistics
Diff. R2 F Diff. df1 df2 p
1 1 .243a 0.059 0.046 0.059 4.641 1 74 0.034
2 1 .302b 0.091 0.079 0.091 7.231 1 72 0.009
3 1 .393c 0.155 0.138 0.155 9.342 1 51 0.004
4 1 .315d 0.099 0.076 0.099 4.285 1 39 0.045
5 1 .584e 0.341 0.281 0.341 5.698 1 11 0.036
2 .784f 0.615 0.538 0.274 7.104 1 10 0.024
6 1 .893g 0.797 0.774 0.797 35.244 1 9 0.000
FU 1 .312h 0.098 0.079 0.098 5.193 1 48 0.027
aPredictors at visit 1 (v1): (constant), concentrating on other positive aspect; bPredictors at visit 2 (v2): (constant), concentration on other positive 
aspect; cPredictors at visit 3 (v3): (constant), anxiety; dPredictors at visit 4 (v4): (constant), depression; ePredictors at visit 5 (v5): (constant), anxiety; 
fPredictors at v5: (constant), anxiety, acceptance; gPredictors at visit 6 (v6): (constant), Catastrophising; hPredictors at follow-up visit (FU): (constant), 
depression; Dependent variable: Cancer related fatigue (CRF) at v1, v2, v3, v4, v5, v6 & FU; R —regression coefficient; R2 — the coefficient of deter-
mination; F — Fischer statistic; Diff. — difference; df — degrees of freedom; p — p-value 
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crucial to continue multicentre research to address an 
issues of psychological and medical aspects of clinical 
response to the chemotherapy and CRF designed for 
larger cancer patients’ group.
Conclusions
High level of adaptive coping strategies and low 
level of non-adaptive ones are the predictors of 
CRF. Emotional state of NSCLC patients undergo-
ing palliative chemotherapy is the significant fac-
tor characterising level of perceived fatigue. More 
often observed symptoms of depression and higher 
level of anxiety are the predictors of perceived CRF. 
Due to the size of the studied group the results of 
this study should be interpreted with caution and 
further research should be undertaken to verify 
these findings.
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